Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma

Current Cancer Drug Targets

Volumn 12, Issue 1, 2012, Pages 14-22

  Miyamoto, H ^a   Zheng, Y ^a   Izumi, K ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Androgen; Bladder cancer; Estrogen; Glucocorticoid; Nuclear receptor; Progesterone; Retinoid; Vitamin D

Indexed keywords

ANDROGEN RECEPTOR; CYTOTOXIC AGENT; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUTAMIDE; GLUCOCORTICOID RECEPTOR; GLUCURONOSYLTRANSFERASE; MESSENGER RNA; NUCLEAR HORMONE RECEPTOR; NUCLEAR PROTEIN; NUCLEAR RECEPTOR NUR77; NUCLEAR RECEPTOR RELATED FACTOR 1; PROGESTERONE RECEPTOR; RALOXIFENE; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

BLADDER; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GROWTH; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; DRUG POTENTIATION; HUMAN; NONHUMAN; PATIENT SELECTION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84862924597     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912798888965     Document Type: Review

References (103)

1. Goebell, P. J.; Knowles, M. A. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol. Oncol. 2010, 28, 409-428.
2. Miyamoto, H.; Miller, J. S.; Fajardo, D. A.; Lee, T. K.; Netto, G. J.; Epstein, J. I. Non-invasive papillary urothelial neoplasms: The 2004 WHO/ISUP classification system. Pathol. Int. 2010, 60, 1-8.
3. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60, 277-300.
4. Scosyrev, E.; Noyes, K.; Feng, C.; Messing, E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 2009, 115, 68-74.
5. Miyamoto, H.; Messing, E. M.; Chang, C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004, 61, 332-353.
6. Barnadas, A.; Gil, M.; Sánchez-Rovira, P.; Llombart, A.; Adrover, E.; Estevez, L. G.; de la Haba, J.; Calvo, L. Neoadjuvant endocrine therapy for breast cancer: Past, present and future. Anticancer Drugs 2008, 19, 339-347.
7. Rosenzweig, B. A.; Bolina, P. S.; Birch, L.; Moran, C.; Marcovici, I.; Prins, G. S. Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit. Neurourol. Urodyn. 1995, 14, 87-96.
8. Wilson, C. M.; McPhaul, M. J. A and B forms of the androgen receptor are expressed in a variety of human tissues. Mol. Cell. Endocrinol. 1996, 120, 51-57.
9. Pelletier, G. Localization of androgen and estrogen receptors in rat and primate tissues. Histol. Histopathol. 2000, 15, 1261-1270.
10. Salmi, S.; Santti, R.; Gustafsson, J.-Å.; Makela, S. Co-localization of androgen receptor with estrogen receptor β in the lower urinary tract of the male rat. J. Urol. 2001, 166, 674-677.
11. Celayir, S.; Ilçe, Z.; Dervisoglu, S. The sex hormone receptors in the bladder in childhood-I. Preliminary report in male subjects. Eur. J. Pediatr. Surg. 2002, 12, 312-317.
12. Hall, R.; Andrews, P. L. R.; Hoyle, C. H. V. Effects of testosterone on neuromuscular transmission in rat isolated urinary bladder. Eur. J. Pharmacol. 2002, 449, 301-309.
13. Purves-Tyson, T. D.; Arshi, M. S.; Handelsman, D. J.; Cheng, Y; Keast, J. R. Androgen and estrogen receptor-mediated mechanisms of testosterone action in male rat pelvic autonomic ganglia. Neuroscience 2007, 148, 92-104.
14. Filippi, S.; Morelli, A.; Sandner, P.; Fibbi, B.; Mancina, R.; Marini, M.; Gacci, M.; Vignozzi, L.; Vannelli, G. B.; Carini, M.; Forti, G.; Maggi, M. Characterization and functional role of androgendependent PDE5 activity in the bladder. Endocrinology 2007, 148, 1019-1029.
15. Juan, Y.-S.; Onal, B.; Broadaway, S.; Cosgrove, J.; Leggett, R. E.; Whitbeck, C.; De, E.; Sokol, R.; Levin, R. M. Effect of castration on male rabbit lower urinary tract tissue enzymes. Mol. Cell. Biochem. 2007, 301, 227-233.
16. Madeiro, A.; Girão, M.; Sartori, M.; Acquaroli, R.; Baracat, E.; Rodrigues de Lima, G. Effects of the association of androgen/estrogen on the bladder and urethra of castrated rats. Clin. Exp. Obstet. Gynecol. 2002, 29, 117-120.
17. Litman, H. J.; Bhasin, S.; O'Leary, M. P.; Link, C. L.; McKinley, J. B. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey. BJU Int. 2007, 100, 321-326.
18. Koritsiadis, G.; Stravodimos, K.; Koutalellis, G.; Agrogiannis, G.; Koritsiadis, S.; Lazaris, A.; Constantinides, C. Androgens and bladder outlet obstruction: a correlation with pressure-flow variables in a preliminary study. BJU Int. 2008, 101, 1542-1546.
19. Holmäng, S.; Mårin, P.; Lindstedt, G.; Hedelin, H. Effect of longterm oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 1993, 23, 99-106.
20. Yassin, A. A.; El-Sakka, A. L.; Saad, F.; Gooren, L. J. G. Lower urinary-tract symptoms and testosterone in elderly men. World J. Urol. 2008, 26, 359-364.
21. Mäkelä, S.; Strauss, L.; Kuiper, G.; Valve, E.; Salmi, S.; Santti, R.; Gustafsson, J. Å. Differential expression of estrogen receptors alpha and beta in adult rat accessory sex glands and lower urinary tract. Mol. Cell. Endocrinol. 2000, 170, 219-229.
22. Blakeman, P. J.; Hilton, P.; Bulmr, J. N. Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. BJU Int. 2000, 86, 32-38.
23. Rizk, D. E.; Raaschou, T.; Mason, N.; Berg, B. Evidence of progesterone receptors in the mucosa of the urinary bladder. Scand. J. Urol. Nephrol. 2001, 35, 305-309.
24. Savolainen, S.; Santti, R.; Streng, T.; Gustafsson, J.-Å.; Härkönen, P.; Mäkelä, S. Sex specific expression of progesterone receptor in mouse lower urinary tract. Mol. Cell. Endocrinol. 2005, 250, 17-21.
25. Teng, J.; Wang, Z.-Y.; Jarrard, D. F.; Bjorling, D. E. Roles of estrogen receptor α and β in modulating urothelial cell proliferation. Endocr. Rel. Cancer 2008, 15, 351-364.
26. Tincello, D. G.; Taylor, A. H.; Spurling, S. M.; Bell, S. C. Receptor isoforms that mediate estrogen and progestagen action in the female lower urinary tract. J. Urol. 2009, 181, 1474-1482.
27. Chavalmane, A. K.; Comeglio, P.; Morelli, A.; Filippi, S.; Fibbi, B.; Vignozzi, L.; Sarchielli, E.; Marchetta, M.; Failli, P.; Sandner, P.; Saad, F.; Gacci, M.; Vannelli, G. B.; Maggi, M. Sex steroid receptors in male human bladder: Expression and biological function. J. Sex. Med. 2010, 7, 2698-2713.
28. McCully, K. S.; Jackson, S. Hormone replacement therapy and the bladder. J. Br. Menopause Soc. 2004, 10, 30-32.
29. Tantiwongse, K.; Fandl, T. M.; Wang, G.; Breyer, B. N.; Walsh, T. J.; Bella, A. J.; Lue, T. F. The potential of hormones and selective oestrogen receptor modulators in preventing voiding dysfunction in rats. BJU Int. 2008, 102, 242-246.
30. Schröder, A.; Pandita, R. K.; Hedlund, P.; Warner, M.; Gustafsson, J.-Å.; Andersson, K.-L. Estrogen receptor subtypes and afferent signaling in the bladder. J. Urol. 2003, 170, 1013-1016.
31. Imamov, O.; Yakimchuk, K.; Moranl, A.; Schwend, T.; Wada-Hiraike, O.; Razumov, S.; Warner, M.; Gustafsson, J.-Å. Estrogen receptor β-deficient female mice develop a bladder phenotype resembling human interstitial cystitis. Proc. Natl. Acad. Sci. USA 2007, 104, 9806-9809.
32. Dyban, P. A.; Sapronoy, N. S. Effect of hydrocortisone on DNA synthesis by urinary bladder epithelial cells and renal cortical substance and on the concentration of glucocorticoids in the blood. Biull. Eksp. Biol. Med. 1977, 83, 569-570.
33. Garty, H.; Peterson-Yamamoto, K.; Asher, C.; Civian, M. M. Effects of corticoid agonists and antagonists on apical Na+ permeability of toad urinary bladder. Am. J. Physiol. 1994, 266, F108-F116.
34. Crescioli, C.; Morelli, A.; Adorini, L.; Ferruzzi, P.; Luconi, M.; Vannelli, G. B.; Marini, M.; Gelmini, S.; Fibbi, B.; Donati, S.; Villari, D.; Forti, G.; Colli, E.; Andersson, K. E.; Maggi, M. Human bladder as a novel target for vitamin D receptor ligands. J. Clin. Endocrinol. Metab. 2005, 90, 962-972.
35. Morelli, A.; Vignozzi, L.; Filippi, S.; Vannelli, G. B.; Ambrosini, S.; Mancina, R.; Crescioli, C.; Donati, S.; Fibbi, B.; Colli, E.; Adorini, L.; Maggi, M. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate 2007, 67, 234-247.
36. Johanning, G. L.; Cope, M. B.; Wilborn, T.; Grubbs, C. J.; Lubet, R. A. Effect of high retinoid doses on RAR-β mRNA expression in female B6D2F1 mice. Anticancer Res. 2011, 21, 1691-1695.
37. Chopra, B.; Hinley, J.; Oleksiewicz, M. B.; Southgate, J. Transspecies comparison of PPAR and RXR expression by rat and human urothelial tissues. Toxicol. Pathol. 2008, 36, 485-495.
38. Loar, E.; Schiffman, Z. J.; Braunstein, J. D.; Reid, R. E.; Tolia, B. M.; Koss, L. G.; Freed, S. Z. Androgen receptor in bladder tumors. Urology 1985, 25, 161-163.
39. Noronha, R. F.; Rao, B. R. Sex hormone receptors in localized and advanced transitional cell carcinoma of urinary tract in humans. Urology 1986, 28, 401-403.
40. Zhuang, Y.-H.; Bläuer, M.; Tammela, T.; Tuohimaa, P. Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology 1997, 30, 556-562.
41. Birtle, A. J.; Freeman, A.; Munson, P. The androgen receptor revisited in urothelial carcinoma. Histopathology 2004, 45, 98-99.
42. Kirkali, Z.; Cowan, S.; Leake, R. E. Androgen receptors in transitional cell carcinoma. Int. Urol. Nephrol. 1990, 22, 231-234.
43. Boorjian, S. A.; Ugras, S.; Mongan, N. P.; Gudas, L. J.; You, X.; Tickoo, S. K.; Scherr, D. S. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 2004, 64, 383-388.
44. Boorjian, S.; Heemers, H. V.; Frank, I.; Farmer, S. A.; Schmidt, L. J.; Sebo, T. J.; Tindall, D. J. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr. Rel. Cancer 2009, 16, 123-137.
45. Tuygun, C.; Kankaya, D.; Imamoglu, A.; Sertcelik, A.; Zengin, K.; Oktay, M.; Sertcelik, N. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: A comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol. Oncol. 2011, 29, 43-51.
46. Mir, C.; Shariat, S. F.; van der Kwast, T. H.; Ashfaq, R.; Lotan, Y.; Evans, A.; Skeldon, S.; Hanna, S.; Vajpeyi, R.; Kuk, C.; Alkhateeb, S.; Morote, J.; van Rhijn, B. W. G.; Bostrom, P.; Yao, J.; Miyamoto, H.; Jewett, M.; Fleshner, N.; Messing, E.; Zlotta, A. R. Loss of androgen receptor expression is not associated with pathological grade, stage, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int. 2010, 108, 24-30.
47. Miyamoto, H.; Yang, Z.; Chen, Y.-T.; Ishiguro, H.; Uemura, H.; Kubota, Y.; Nagashima, Y.; Chang, Y.-J.; Hu, Y.-C.; Tsai, M.-Y.; Yeh, S.; Messing, E. M.; Chang, C. Promotion of bladder cancer development and progression by androgen receptor signals. J. Natl. Cancer Inst. 2007, 99, 558-568.
48. Miyamoto, H.; Yao, J. L.; Chuax, A. M.; Zheng, Y.; Hsu, I.; Izumi, K.; Chang, C.; Messing, E. M.; Netto, G. J.; Yeh, S. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int. 2011, in press.
49. Chen, F.; Langenstroer, P.; Zhang, G.; Iwamoto, Y.; See, W. A. Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines. J. Urol. 2003, 170, 2009-2013.
50. Johnson, A. M.; O'Connell, M. J.; Miyamoto, H.; Huang, J.; Yao, J. L.; Messing, E. M.; Reeder, J. E. Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospodin-1. BMC Urol. 2008, 8, 7.
51. Wu, J.-T.; Han, B.-M.; Yu, S.-Q.; Wang, H.-P.; Xia, S.-J. Androgen receptor is a potential therapeutic target for bladder cancer. Urology 2009, 75, 820-827.
52. Cheng, L.; MacLennan, G. T.; Pan, C.-X.; Jones, T. D.; Moore, C. R.; Zhang, S.; Gu, J.; Patel, N. B.; Kao, C.; Gardner, T. A. Allelic loss of the active X chromosome during bladder carcinogenesis. Arch. Pathol. Lab. Med. 2004, 128, 187-190.
53. Teng, X.-Y.; Liu, G.-Q.; Diao, X.-L.; Wu, Z.-Y.; Li, L.; Zhang, W.; Zhang, X.; Su, Q. CAG repeats in the androgen receptor gene are shorter in patients with pulmonary, esophageal or bladder carcinoma and longer in women with uterine leiomyoma. Oncol. Rep. 2010, 23, 811-818.
54. Ohtani, M.; Kakizoe, T.; Nishio, Y.; Sato, S.; Sugimura, T.; Fukushima, S.; Niijima, T. Sequential changes of mouse bladder epithelium during induction of invasive carcinomas by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res. 1986, 46, 2001-2004.
55. Bertram, J. S.; Craig, A. W. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur. J. Cancer 1972, 8, 587-594.
56. Okajima, E.; Hiramatsu, T.; Iriya, K.; Ijuin, M.; Matsushima, S.; Yamada, K. Effects of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Urol. Res. 1975, 3, 73-79.
57. Imada, S.; Akaza, H.; Ami, Y.; Koiso, K.; Ideyama, Y.; Takenaka, T. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur. Urol. 1997, 31, 360-364.
58. Saikawa, S.; Kanamaru, H.; Noriki, S.; Matsukawa, S.; Okada, K. The effects of organ resection on rat urinary bladder carcinogenesis. Urol. Res. 2001, 29, 210-215.
59. Reid, L. M.; Leav, I.; Kwan, P. W. L.; Russell, P.; Merk, F. B. Characterization of a human, sex steroid-responsive transitional cell carcinoma maintained as a tumor line (R198) in athymic nude mice. Cancer Res. 1984, 44, 4560-4573.
60. Imaoka, S.; Yoneda, Y.; Sugimoto, T.; Ikemoto, S.; Hiroi, T.; Yamamoto, K.; Nakatani, T.; Funae, Y. Androgen regulation of CYP4B1 responsible for mutagenic activation of bladder carcinogens in the rat bladder: detection of CYP4B1 mRNA by competitive reverse transcription-polymerase chain reaction. Cancer Lett. 2001, 166, 119-123.
61. Izumi, K.; Zheng, Y.; Hsu, J.-W.; Chang, C.; Miyamoto, H. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: A potential mechanism of androgen-induced bladder carcinogenesis. Mol. Carcinog. 2011, in press.
62. Yang, Z.; Chang, Y.-J.; Yu, I.-C.; Yeh, S.; Wu, C.-C.; Miyamoto, H.; Merry, D. E.; Sobue, G.; Chen, L.-M.; Chang, S.-S.; Chang, C. ASCJ-9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nature Med. 2007, 13, 348-353.
63. Zheng, Y.; Izumi, K.; Yao, J. L.; Miyamoto, H. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr.-Rel. Cancer 2011, 18, 451-464.
64. Kaufmann, O.; Baume, H.; Dietel, M. Detection of oestrogen receptors in non-invasive and invasive transitional cell carcinomas of the urinary bladder using both conventional immunohistochemistry and the tyramide staining amplification (TSA) technique. J. Pathol. 1998, 186, 165-168.
65. Basakci, A.; Kirkali, Z.; Tuzel, E.; Yorukoglu, K.; Mungan, M. U.; Sade, M. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur. Urol. 2002, 41, 342-345.
66. Shen, S. S.; Smith, C. L.; Hsieh, J.-T.; Yu, J.; Kim, I. Y.; Jian, W.; Sonpavde, G.; Ayala, G. E.; Younes, M. Y.; Lerner, S. P. Expression of estrogen receptor-α and-β in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006, 106, 2610-2616.
67. Bolenz, C.; Lotan, Y.; Ashfaq, R.; Shariat, S. F. Estrogen and progesterone hormone receptor expression in urothelial carcinoma of the bladder. Eur. Urol. 2009, 56, 1093-1095.
68. Anghel, A.; Anghel, A.; Narita, D.; Seclaman, E.; Popovici, E.; Anghel, M.; Tamas, L. Estrogen receptor alpha polymorphisms and the risk of malignancies. Pathol. Oncol. Res. 2010, 16, 485-496.
69. Croft, P. R.; Lathrop, S. L.; Feddersen, R. M.; Joste, N. E. Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma. Arch. Pathol. Lab. Med. 2005, 129, 194-199.
70. Kontos, S.; Kominea, A.; Melachrinou, M.; Balampani, E.; Sotiropoulou-Bonikou, G. Inverse expression of estrogen receptor-β and nuclear factor-κβ in urinary bladder carcinogenesis. Int. J. Urol. 2010, 17, 801-810.
71. Diamanti-Kandarakis, E. Hormone replacement therapy and risk of malignancy. Curr. Opin. Obstet. Gynecol. 2004, 16, 73-78.
72. Cantwell, M. M.; Lacey, Jr. J. V.; Schairer, C.; Schatzkin, A.; Michaud, D. S. Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study. Int. J. Cancer 2006, 119, 2398-2401.
73. Cantor, K. P.; Lynch, C. F.; Johnson, D. Bladder cancer, parity, and age at first birth. Cancer Causes Control 1992, 3, 57-62.
74. Wolpert, B. J.; Amr, S.; Ezzat, S.; Saleh, D.; Gouda, I.; Loay, I.; Hifnawy, T.; Mikhail, N. N.; Abdel-Hamid, M.; Zhan, M.; Zheng, Y.-L.; Squibb, K.; Abdel-Aziz, M. A.; Zaghloul, M.; Khaled, H.; Loffredo, C. A. Estrogen exposure and bladder cancer risk in Egyptian women. Maturitas 2010, 67, 353-357.
75. Johnson, A. M.; O'Connell, M. J.; Messing, E. M.; Reeder, J. E. Decreased bladder cancer growth in parous mice. Urology 2008, 72, 470-473.
76. Chen, C.-H.; Chiou, H.-Y.; Hsueh, Y.-M.; Chen, C.-J.; Yu, H.-J.; Pu, Y.-S. Clinocopathological characteristics and survival outcome of arsenic related bladder cancer in Taiwan. J. Urol. 2009, 181, 547-553.
77. Shen, J.; Wanibuchi, H.; Waalkes, M. P.; Salim, E. I.; Kinoshita, A.; Yoshida, K.; Endo, G.; Fukushima, S. A comparative study of the sub-chronic toxic effects of three organic arsenical compounds on the urothelium in F344 rats; gender-based differences in response. Toxicol. Appl. Pharmacol. 2006, 210, 171-180.
78. Suzuki, S.; Arnold, L. L.; Ohnishi, T.; Cohen, S. M. Effects of inorganic arsenic on the rat and mouse urinary bladder. Toxicol. Sci. 2008, 106, 350-363.
79. Waalkes, M. P.; Liu, J.; Ward, J. M.; Powell, D. A.; Diwan, B. A. Urogenital carcinogenesis in female CD1 mice induced by in utero arsenic exposure is exacerbated by postnatal diethylstilbestrol treatment. Cancer Res. 2006, 66, 1337-1345.
80. Davey, J. C.; Bodwell, J. E.; Gosse, J. A.; Hamilton, J. W. Arsenic as an endocrine disruptor: Effects of arsenic on estrogen receptormediated gene expression in vivo and in cell culture. Toxicol. Sci. 2007, 98, 75-86.
81. Sonpavde, G.; Okuno, N.; Weiss, H.; Yu, J.; Shen, S. S.; Younes, M.; Jian, W.; Lerner, S. P.; Smith, C. L. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. Urology 2007, 69, 1221-1226.
82. Kim, H. T.; Kim, B. C.; Kim, I. Y.; Mamura, M.; Seong, D. H.; Jang, J.-J.; Kim, S.-J. Raloxifene, a mixed estrogen agonist/antagonist, induces apotosis through cleavage of BAD in TSU-PR1 human cancer cells. J. Biol. Chem. 2002, 277, 32510-32515.
83. Hsu, C.-H.; Chen, J.; Wu, C.-Y.; Cheng, A.-L.; Pu, Y.-S. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res. 2001, 21, 711-715.
84. Dietrich, K.; Schned, A.; Fertuny, J.; Heaney, J.; Marsit, C.; Kelsey, K. T.; Karagas, M. R. Glucocorticoid therapy and risk of bladder cancer. Br. J. Cancer 2009, 101, 1316-1320.
85. Mondul, A. M.; Weinstein, S. J.; Männistö, S.; Snyder, K.; Horst, R. L.; Virtamo, J.; Albanes, D. Serum vitamin D and risk of bladder cancer. Cancer Res. 2010, 70, 9218-9223.
86. Mittal, R. D.; Manchanda, P. K.; Bhat, S.; Bid, H. K. Association of vitamin-D receptor (Fok-1) gene polymorphism with bladder cancer in an Indian population. BJU Int. 2007, 99, 933-937.
87. 3 receptor expression in superficial transitional cell carcinoma of the bladder: A possible prognostic factor? Eur. Urol. 2005, 47, 52-57.
88. Konety, B. R.; Lavelle, J. P.; Pirtskalaishvili, G.; Dhir, R.; Meyers, S. A.; Nguyen, T. S.; Hershberger, P.; Shurin, M. R.; Johnson, C. S.; Trump, D. L.; Zeidel, M. L.; Getzenberg, R. H. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder In vitro and in vivo. J. Urol. 2001, 165, 253-258.
89. Abedin, S. A.; Thorne, J. L.; Battaglia, S.; Maguire, O.; Hornung, L. B.; Doherty, A. P.; Mills, I. G.; Camphell, M. J. Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. Carcinogenesis 2009, 30, 449-456.
90. Lippman S. M.; Lotan, R. Advances in the development of retinoids as chemopreventive agents. J. Nutr. 2000, 130, 479S-482S.
91. Becci, P. J.; Thompson, H. J.; Grubbs, C. J.; Squire, R. A.; Brown, C. C.; Sporn, M. B.; Moon, R. C. Inhibitory effect of 13-cisretinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Cancer Res. 1978, 38, 4463-4466.
92. Zou, C.; Zhou, J.; Qian, L.; Feugang, J. M.; Liu, J.; Wang, X.; Wu, S.; Ding, H.; Zou, C.; Liebert, M.; Grossman, H. B. Comparing the effect of ATRA, 4-HPR, and CD437 in bladder cancer cells. Front. Biosci. 2006, 11, 2007-2016.
93. Hurst, R. E.; Waliszewski, P.; Waliszewska, M.; Bonner, R. B.; Benbrook, D. M.; Dar, A.; Hermstreet, G. P. III. Complexity, retinoid-responsive gene networks, and bladder carcinogenesis. Adv. Exp. Med. Biol. 1999, 462, 449-467.
94. 2M arrest and apoptosis in bladder cancer cells. Int. J. Cancer 2005, 115, 917-923.
95. Boorjian, S.; Scherr, D. S.; Mongan, N. P.; Zhuang, Y.; Nanus, D. M.; Gudas, L. J. Retinoid receptor mRNA expression profiles in human bladder cancer specimens. Int. J. Oncol. 2005, 26, 1041-1048.
96. Maruyama, R.; Toyooka, S.; Toyooka, K. O.; Harada, K.; Virmani, A. K.; Zöchbauer-Müller, S.; Farinas, A. J.; Vakar-Lopez, F.; Minne, J. D.; Sagalowsky, A.; Czemiak, B.; Gazdar, A. F. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001, 61, 8659-8663.
97. Chan, M. W. Y.; Chan, L. W.; Tang, N. L. S.; Tong, J. H. M.; Lo, K. W.; Lee, T. L.; Cheung, H. Y.; Wong, W. S.; Chan, P. S. F.; Lai, F. M. M.; To, K. F. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin. Cancer Res. 2002, 8, 464-471.
98. Guan, Y.-F.; Zheng, Y.-H.; Breyer, R. M.; Davis, L.; Breyer, M. D. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999, 1, 330-339.
99. Kassouf, W.; Chintharlapalli, S.; Abdelrahim, M.; Nelkin, G.; Safe, S.; Kamat, A. M. Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: A new class of peroxisome proliferator-activated receptor γ agonists. Cancer Res. 2006, 66, 412-418.
100. Fauconnet, S.; Lascombe, I.; Chabannes, E.; Adessi, G.-L.; Desvergne, B.; Wahli, W.; Bittard, H. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J. Biol. Chem. 2002, 277, 23535-23543.
101. Inamoto, T.; Czerniak, B. A.; Dinney, C. P.; Kamat, A. M. Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. Cancer 2010, 116, 340-346.
102. Inamoto, T.; Papineni, S.; Chintharlapalli, S.; Cho, S.-D.; Safe, S.; Kamat, A. M. 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Mol. Cancer Ther. 2008, 7, 3825-3833.
103. Cho, S. D.; Lee, S.-O.; Chintharlapalli, S.; Abdelrahim, M.; Khan, S.; Yoon, K.; Kamat, A. M.; Safe, S. Activation of nerve growth factor-induced Bα by methylene-substituted diindolylmethanes in bladder cancer cells induces apoptosis and inhibits tumor growth. Mol. Pharmacol. 2010, 77, 396-404.